We are pleased to share an important milestone for Technophage: the Phase 1/2a clinical study TP-122_101A has recently received the necessary regulatory approvals to move forward in Europe, specifically Portugal and the Netherlands.
The study, entitled “Randomized, Parallel, Open-Label, Phase 1/2a Study to Assess the Safety and Tolerability of Multiple Doses of the Bacteriophage Cocktail TP-122 (Component TP-122A) for the Treatment of Ventilator-Associated Pneumonia”, represents a significant step in the clinical development of bacteriophage-based therapies targeting severe bacterial infections.
This achievement reflects the dedication of our teams, investigators, and partners who have contributed to bringing this program to the clinical stage. We look forward to advancing this important program and sharing further updates as key milestones are reached.
Ventilator-Associated Pneumonia remains a major unmet medical need, particularly in the context of antimicrobial resistance, and we remain committed to advancing innovative phage therapies for patients who need new treatment options.